Patent · US Active

Topical application for an anti-HSV antibody

US11267871B2 · kind B2 · utility

0Cited by

2References

19Claims

0Family size

Assignee

Heiselberg ImmunoTherapeutics GmbH · DE

Inventors

Michaela Arndt · Mannheim, DE
Jürgen Krauss · Wilhelmsfeld, DE
Dirk Jager · New York, US

Key dates

Filing date	Jun 25, 2015
Grant date	Mar 8, 2022
Priority date	—
Expiry date	Jun 25, 2035

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/76
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Described is an anti-HSV antibody or an antigen-binding fragment thereof for use in treating an acute infection of mucosal or epidermal tissue in a subject caused by HSV-1 or HSV-2 selected from the group consisting of Herpes simplex labialis, Herpes simplex genitalis, chronic or disseminated cutaneous herpes simplex infection, Herpes gladiatorum and Eczema herpeticum, wherein said antibody is to be topically administered as well as to a pharmaceutical composition comprising an effective amount of said antibody or antigen-binding fragment thereof and at least one pharmaceutically acceptable excipient.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.